Skip to main content
S&P 5007,591.70-0.58%DOW52,064.10-0.60%NASDAQ26,081.72-0.65%BTC$76,759.00-1.92%ETH$2,449.71-0.78%GOLD$4,364.00-0.98%OIL$103.08+0.59%
Smart Investors Daily
RE

NASDAQ · REPL

Replimune Group, Inc.

Healthcare · Biotechnology

$14.45

Down-$1.21 (-8.37%)

Updated Sep 11, 2026, 12:40 AM

SID Score

6.2/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
774.6M
P/E ratio
-3.23
Dividend yield
0.00%
52-week range
$1.50 – $16.33
Volume
1.07M
Avg. volume
5.08M

Price performance

REPL price history

1M range · 0 trading sessions · Daily adjusted prices

REPL does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest REPL news

The latest Smart Investors Daily articles mentioning REPL.

Stock researchCompany · Overview

REPL research

Overview

Company profile and research snapshot.

Company profile

Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$13.67
Implied upside
—
Analysts
—
REPL recent ratings
DateFirmRatingTarget
Aug 26, 2026JP MorganOverweight—
Aug 7, 2026JP MorganOverweight—
Aug 7, 2026WedbushOutperform—
Aug 4, 2026Leerink PartnersOutperform—
Jul 31, 2026Cantor FitzgeraldOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 3, 2026

Replimune to Present at the Cantor Global Healthcare Conference 2026

WOBURN, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a commercial stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that members of the Replimune management team will present in a fireside chat at the Cantor Global Healthcare Conference on Thursday, September 10 at 9:10 AM ET. A simultaneous webcast will be available in the Investors section of Replimune’s website at replimune.com. A replay will be availa

Benzinga · Aug 14, 2026

Replimune Group Q1 EPS $(0.72) Beats $(0.73) Estimate

Replimune Group (NASDAQ:REPL) reported quarterly losses of $(0.72) per share which beat the analyst consensus estimate of $(0.73) by 1.37 percent. This is a 24.21 percent increase over losses of $(0.95) per share from

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By